Insider · CIK 0001325710
Matthew L Sherman
Files at DCPH (Deciphera Pharmaceuticals, Inc.). First filing Jan 19, 2023, latest Feb 20, 2024.
In brief
Matthew L Sherman files SEC Form 4 as officer at DCPH (Deciphera Pharmaceuticals, Inc.). Since Jan 19, 2023, Matthew L Sherman has reported 0 open-market buys worth $0 and 7 open-market sells worth $237k, the latest filed on Feb 20, 2024.
A track record needs three past buys with six months of prices behind them; Matthew L Sherman has 0, so none is measured yet.
The newest scored trade: sold $41k of DCPH on Feb 16, 2024, filed Feb 20, 2024, scored 36 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Deciphera Pharmaceuticals, Inc. | $41k 2,615 shares | -2% | - | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | $35k 2,435 shares | -3% | - | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | $43k 2,792 shares | -3% | - | |
| 35Weak | Deciphera Pharmaceuticals, Inc. | $28k 2,360 shares | -3% | - | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | $24k 1,655 shares | -2% | - | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | $15k 971 shares | -1% | - | |
| 37Weak | Deciphera Pharmaceuticals, Inc. | $51k 2,403 shares | -3% | - |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +34,157 | - | - | 144,290 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -72,029 | - | - | 72,261 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | UTender of shares Common Stock | -72,261 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -82,265 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -82,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -65,900 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -69,100 | - | - | 0 | Jun 11, 2024 |
| Feb 15, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +17,275 | $0.00 | $0 | 111,354 | Feb 20, 2024 |
| Feb 16, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,615 | $15.62 | $41k | 108,739 | Feb 20, 2024 |
| Feb 15, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +69,100 | $0.00 | $0 | 69,100 | Feb 20, 2024 |
| Jan 16, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,435 | $14.47 | $35k | 94,079 | Jan 18, 2024 |
| Dec 12, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +8,244 | - | - | 99,306 | Dec 14, 2023 |
| Dec 13, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,792 | $15.37 | $43k | 96,514 | Dec 14, 2023 |
| Oct 28, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +8,244 | - | - | 92,988 | Oct 31, 2023 |
| Oct 30, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,360 | $12.02 | $28k | 90,628 | Oct 31, 2023 |
| Jun 16, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,655 | $14.40 | $24k | 87,686 | Jun 21, 2023 |
| Feb 15, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +16,488 | $0.00 | $0 | 89,116 | Feb 17, 2023 |
| Feb 16, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -971 | $15.10 | $15k | 88,145 | Feb 17, 2023 |
| Feb 15, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +65,900 | $0.00 | $0 | 65,900 | Feb 17, 2023 |
| Jan 17, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,403 | $21.24 | $51k | 72,628 | Jan 19, 2023 |
Questions about Matthew L Sherman
Answered from the filings on this page, as of the latest one.
Is Matthew L Sherman buying or selling?
Not in the last 12 months. Matthew L Sherman's latest open-market trade on SEC Form 4 was sold $41k of DCPH on Feb 16, 2024.
How did Matthew L Sherman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew L Sherman has 0.
Where does Matthew L Sherman file Form 4?
Matthew L Sherman has filed Form 4 at DCPH (Deciphera Pharmaceuticals, Inc.) as EVP & Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.